News headlines about CTI BioPharma Corp. (NASDAQ:CTIC) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CTI BioPharma Corp. earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.5375719573287 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of research analysts have weighed in on CTIC shares. Jefferies Group LLC started coverage on shares of CTI BioPharma Corp. in a research report on Tuesday, September 12th. They set a “buy” rating and a $7.50 target price for the company. ValuEngine lowered shares of CTI BioPharma Corp. from a “sell” rating to a “strong sell” rating in a research report on Wednesday.
CTI BioPharma Corp. (NASDAQ:CTIC) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.63. The company had revenue of $22.23 million during the quarter. CTI BioPharma Corp. had a negative net margin of 136.76% and a negative return on equity of 418.99%.
In other news, Director Richard L. Love sold 14,600 shares of the firm’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $3.21, for a total transaction of $46,866.00. Following the completion of the sale, the director now owns 84,318 shares in the company, valued at approximately $270,660.78. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 8.08% of the company’s stock.
TRADEMARK VIOLATION WARNING: “CTI BioPharma Corp. (CTIC) Receives Media Impact Score of 0.14” was reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.truebluetribune.com/2017/10/13/cti-biopharma-corp-ctic-receives-media-impact-score-of-0-14.html.
CTI BioPharma Corp. Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.